Protein engineering

EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Wednesday, March 13, 2024

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Key Points: 
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    The issuer is solely responsible for the content of this announcement.
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading provider of solutions for the biologization of industry, and AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, announce the successful completion of the first phase of a development collaboration.
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech’s rational design in protein engineering.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner.”

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

Retrieved on: 
Wednesday, March 6, 2024

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.
  • As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction.
  • Daniel J. O’Connor, Chief Executive Officer of Ambrx, said, “We want to thank our shareholders for their strong support of this transaction.
  • Ambrx now expects to complete the transaction on or about March 7, 2024, subject to the satisfaction of customary closing conditions.

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024

PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.

Key Points: 
  • PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.
  • The upcoming abstracts highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, protein engineering and computational biology.
  • Additionally, the Company will share new preclinical data on additional Allo-Evasion™ edits that could further support Century’s multi-dosing strategy.
  • Details of the poster presentations are as follows:
    Full abstracts are currently available through the AACR conference website.

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Retrieved on: 
Tuesday, March 5, 2024

CHATHAM, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the results of modeling key human pharmacokinetic (PK) properties for TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* from animal studies. TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplantation and for the treatment of autoimmune disorders.

Key Points: 
  • TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplantation and for the treatment of autoimmune disorders.
  • “Preclinical studies in non-human primates have shown that TNX-1500 maintains the activity of first generation mAbs, with reduced risk of thrombotic complications.3-5 Today we are announcing that modeling studies from animal PK data3, predict that a half-life of approximately three weeks for TNX-1500 in humans6,7, which supports monthly dosing.
  • or biweekly s.c. dosing regimens.2 Based on its results in multiple sclerosis, Sanofi projects that frexalimab will exceed €5B per year in peak sales1.
  • TNX-1500 was designed to reduce binding to the Fc-receptor for IgG type 2a, or FcγR2a, which has been shown to play a role in the thrombosis associated with first-generation anti-CD40L mAbs, similar to frexalimab.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, March 4, 2024

The stock options have an exercise price of $5.39 per share, which is equal to the closing price per share of the Company’s ordinary shares as reported by Nasdaq on March 1, 2024.

Key Points: 
  • The stock options have an exercise price of $5.39 per share, which is equal to the closing price per share of the Company’s ordinary shares as reported by Nasdaq on March 1, 2024.
  • Each of the stock options is subject to the terms and conditions of a stock option award agreement covering the grant and the Company’s 2024 Inducement Stock Option and Incentive Plan.
  • The restricted stock units vest over four years, 25% per year on the anniversary of the grant date, subject to such employee’s continued service with the Company through the applicable vesting dates.
  • Each of the restricted stock units is subject to the terms and conditions of a restricted stock award agreement covering the grant and the Company’s 2024 Inducement Stock Option and Incentive Plan.

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Retrieved on: 
Wednesday, February 28, 2024

CHATHAM, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy volunteers. TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.

Key Points: 
  • TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.
  • “Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Anti-CD40L modulates T cell function and has the potential to promote tolerance of transplanted organs.
  • We are excited to have completed the clinical stage of this Phase 1 trial of TNX-1500, a third-generation Fc-modified anti-CD40L mAb that has been designed by protein engineering to eliminate the risk of thrombosis associated with first-generation anti-CD40L mAbs.

Autolus Therapeutics announces publication in Nature Communications 

Retrieved on: 
Thursday, February 22, 2024

LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication in Nature Communications entitled: ‘Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies.’1

Key Points: 
  • LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication in Nature Communications entitled: ‘Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies.’1
    In contrast to B cell lymphomas, T cell lymphomas have not benefited from immunotherapies such as therapeutic antibodies or CAR T cell therapies.
  • Immunotherapies for B cell lymphomas target pan B cell antigens, however an equivalent strategy targeting pan T cell antigens would lead to unacceptable immunosuppression.
  • Autolus is developing therapeutic approaches which exploit this biology and has developed AUTO4, a CAR which selectively targets TRBC12.
  • In this publication, the research team at Autolus first describe the structural basis for selective AUTO4 CAR recognition of TRBC1.

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

Retrieved on: 
Thursday, March 7, 2024

The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.

Key Points: 
  • The Company’s model uniquely combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand's patented HYFT Technology.
  • Central to the success of BioStrand's Foundation AI Model is its utilization of its patented HYFT technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere.
  • The Advanced Foundation AI model employs a distinctive approach known as "LLM stacking" to intelligently combine different LLMs, with the HYFTs linked to specific features found in various LLMs.
  • Our presentation will focus on introducing our groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

Playground Global Promotes Benjamin Kim PhD to Partner

Retrieved on: 
Wednesday, February 28, 2024

Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.

Key Points: 
  • Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.
  • View the full release here: https://www.businesswire.com/news/home/20240228985705/en/
    Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University.
  • “It’s an honor to contribute to the Playground life sciences ecosystem and support our portfolio companies in evolving deeply technical breakthroughs into transformational businesses,” said Ben Kim, PhD, Partner at Playground.
  • “Ben brings an infectious passion for and incredible knowledge of bioengineering and biophysics to the Playground team,” said Jory Bell , General Partner at Playground.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.